Edwards Lifesciences (EW) reported Q4 adjusted earnings late Tuesday of $0.59 per diluted share, up from $0.55 a year earlier.
Analysts polled by FactSet expected $0.55.
Net sales for the quarter ended Dec. 31 rose to $1.39 billion from $1.27 billion a year earlier.
Analysts surveyed by FactSet expected $1.36 billion.
The company said it expects Q1 adjusted EPS of $0.58 to $0.64 on revenue of $1.35 billion to $1.43 billion. Analysts project EPS of $0.59 on revenue of $1.41 billion.
Edwards said its full-year guidance remains unchanged.
Shares of the company were up about 7% in after-hours activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。